These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 22509073)
1. Pancreatic cancer: translational research aspects and clinical implications. Ansari D; Chen BC; Dong L; Zhou MT; Andersson R World J Gastroenterol; 2012 Apr; 18(13):1417-24. PubMed ID: 22509073 [TBL] [Abstract][Full Text] [Related]
2. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978 [TBL] [Abstract][Full Text] [Related]
3. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823 [TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. Tanase CP; Neagu AI; Necula LG; Mambet C; Enciu AM; Calenic B; Cruceru ML; Albulescu R World J Gastroenterol; 2014 Aug; 20(31):10790-801. PubMed ID: 25152582 [TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer stem cells: emerging target for designing novel therapy. Li Y; Kong D; Ahmad A; Bao B; Sarkar FH Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908 [TBL] [Abstract][Full Text] [Related]
8. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. Neureiter D; Jäger T; Ocker M; Kiesslich T World J Gastroenterol; 2014 Jun; 20(24):7830-48. PubMed ID: 24976721 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Fitzgerald TL; McCubrey JA Adv Biol Regul; 2014 Sep; 56():45-50. PubMed ID: 24925031 [TBL] [Abstract][Full Text] [Related]
17. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503 [TBL] [Abstract][Full Text] [Related]
18. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222 [TBL] [Abstract][Full Text] [Related]
19. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Nagathihalli NS; Nagaraju G Biochim Biophys Acta; 2011 Dec; 1816(2):209-18. PubMed ID: 21807066 [TBL] [Abstract][Full Text] [Related]
20. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]